FATE - Fate Therapeutics Inc
IEX Last Trade
3.68
0.140 3.804%
Share volume: 1,046,976
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.54
0.14
3.96%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-03 | 2022-11-03 | 2023-02-28 | 2023-05-03 | 2023-08-08 | 2023-11-08 | 2024-02-26 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 807.059 M | 749.349 M | 705.561 M | 630.336 M | 584.757 M | 543.788 M | 506.217 M | 569.892 M | |
| Current Assets | 599.157 M | 535.329 M | 502.074 M | 437.888 M | 392.182 M | 364.174 M | 331.540 M | 394.375 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 17.181 M | 19.970 M | 27.367 M | 15.490 M | 11.414 M | 12.902 M | 14.539 M | 9.973 M | |
| Short Term Investments | 17.181 M | 19.970 M | 27.367 M | 15.490 M | 11.414 M | 12.902 M | 14.539 M | 9.973 M | |
| Total Receivables | 526.701 M | 433.266 M | 38.480 M | 380.378 M | 333.966 M | 317.938 M | 1.826 M | 858.000 K | |
| Current Cash | 55.275 M | 82.093 M | 436.227 M | 42.020 M | 46.802 M | 33.334 M | 315.175 M | 383.544 M | |
| Total Non-current Assets | 207.902 M | 214.020 M | 203.487 M | 192.448 M | 192.575 M | 179.614 M | 174.677 M | 175.517 M | |
| Property Plant Equipment | 103.116 M | 109.118 M | 110.020 M | 108.594 M | 106.331 M | 101.707 M | 96.836 M | 92.116 M | |
| Other Assets | 9.141 M | 8.358 M | 7.229 M | 33.000 K | 33.000 K | 9.000 K | 9.000 K | 9.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 807.059 M | 749.349 M | 705.561 M | 630.336 M | 584.757 M | 543.788 M | 506.217 M | 569.892 M | |
| Total liabilities | 226.576 M | 231.346 M | 221.622 M | 152.864 M | 147.002 M | 141.011 M | 137.800 M | 143.777 M | |
| Total current liabilities | 91.518 M | 103.938 M | 114.051 M | 48.651 M | 44.690 M | 41.333 M | 39.094 M | 45.369 M | |
| Accounts Payable | 8.420 M | 9.593 M | 8.265 M | 9.855 M | 7.506 M | 5.706 M | 4.719 M | 6.765 M | |
| Other liabilities | 28.471 M | 22.244 M | 3.861 M | 2.143 M | 1.750 M | 701.000 K | 1.346 M | 2.740 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 28.471 M | 22.244 M | 3.861 M | 2.143 M | 1.750 M | 701.000 K | 1.346 M | 2.740 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 580.483 M | 518.003 M | 483.939 M | 477.472 M | 437.755 M | 402.777 M | 368.417 M | 426.115 M | |
| Common stock | 96.704 M | 97.024 M | 97.233 M | 98.055 M | 98.400 M | 98.568 M | 98.622 M | 101.104 M | |
| Retained earnings | -910.878 M | -994.441 M | -1.051 B | -1.070 B | -1.122 B | -1.168 B | -1.212 B | -1.260 B |